{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:51:00Z","timestamp":1790884260400,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310108"],"award-info":[{"award-number":["JP19fk0310108"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0210021"],"award-info":[{"award-number":["JP19fk0210021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310108"],"award-info":[{"award-number":["JP19fk0310108"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310108"],"award-info":[{"award-number":["JP19fk0310108"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0210021"],"award-info":[{"award-number":["JP19fk0210021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310103"],"award-info":[{"award-number":["JP19fk0310103"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0210021"],"award-info":[{"award-number":["JP19fk0210021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310108"],"award-info":[{"award-number":["JP19fk0310108"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310108"],"award-info":[{"award-number":["JP19fk0310108"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0210021"],"award-info":[{"award-number":["JP19fk0210021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mechanisms of hepatitis B virus (HBV) reactivation after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) treatment in HBV\/HCV-co-infected patients remain unclear. We examined RIG-I-like helicase (RLH) pathway activation by HBV mono-infection, HCV mono-infection or HBV\/HCV co-infection and interference between HBV and HCV in primary human hepatocytes. Interference between HBV and HCV and HBV reactivation after DAA treatment in humanized-liver mice were assessed. HCV infection activated RLH pathway, as evidenced by RIG-I, ISG15 and ISG56 expression induction; HBV caused only RIG-I induction <jats:italic>in vitro<\/jats:italic>. RLH activation was also found in HBV\/HCV-co-infected cells, and HBV replication were suppressed in HBV\/HCV-co-infected than in HBV-mono-infected cells. siRNA-mediated double knockdown of ISG15 and ISG56 increased HBV replication in HBV\/HCV-co-infected cells. HCV infection activated RLH pathway and suppressed HBV replication in humanized-liver mice. Subsequent elimination of HCV by DAA administration downregulated RLH pathway and upregulated HBV replication in mice. RLH pathway was activated in livers of chronic hepatitis C patients compared to those of chronic hepatitis B or non-B, non-C patients. The RLH pathway activation was downregulated by HCV elimination. In conclusion, HCV infection activated RLH pathway and suppressed HBV replication in human hepatocytes. HCV elimination upregulated HBV replication, probably through RLH pathway downregulation.<\/jats:p>","DOI":"10.1038\/s41598-020-57603-9","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:04:44Z","timestamp":1579691084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazuhiro","family":"Murai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-4346","authenticated-orcid":false,"given":"Yasuteru","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Yamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Nakabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-2454","authenticated-orcid":false,"given":"Hiroshi","family":"Suemizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Ryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-1324","authenticated-orcid":false,"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-607X","authenticated-orcid":false,"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"57603_CR1","first-page":"783","volume":"104","author":"CJ Liu","year":"2005","unstructured":"Liu, C. J., Liou, J. M., Chen, D. S. & Chen, P. J. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J. Formos. Med. Assoc. 104, 783\u2013791 (2005).","journal-title":"J. Formos. Med. Assoc."},{"key":"57603_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/infdis\/162.4.817","volume":"162","author":"DS Chen","year":"1990","unstructured":"Chen, D. S. et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J. Infect. Dis. 162, 817\u2013822 (1990).","journal-title":"J. Infect. Dis."},{"key":"57603_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1034\/j.1600-0676.2003.00820.x","volume":"23","author":"CJ Liu","year":"2003","unstructured":"Liu, C. J. et al. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int. 23, 148\u2013155 (2003).","journal-title":"Liver Int."},{"key":"57603_CR4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3748\/wjg.v20.i11.2955","volume":"20","author":"CJ Liu","year":"2014","unstructured":"Liu, C. J. & Chen, P. J. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J. Gastroenterol. 20, 2955\u20132961, https:\/\/doi.org\/10.3748\/wjg.v20.i11.2955 (2014).","journal-title":"World J. Gastroenterol."},{"key":"57603_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1023\/A:1007619614350","volume":"15","author":"JR Pall\u00e1s","year":"1999","unstructured":"Pall\u00e1s, J. R., Fari\u00f1as-Alvarez, C., Prieto, D. & Delgado-Rodr\u00edguez, M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur. J. Epidemiol. 15, 699\u2013704 (1999).","journal-title":"Eur. J. Epidemiol."},{"key":"57603_CR6","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/JCM.36.7.2084-2086.1998","volume":"36","author":"CM Chu","year":"1998","unstructured":"Chu, C. M., Yeh, C. T. & Liaw, Y. F. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J. Clin. Microbiol. 36, 2084\u20132086 (1998).","journal-title":"J. Clin. Microbiol."},{"key":"57603_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/jhep.2001.26511","volume":"34","author":"R Jardi","year":"2001","unstructured":"Jardi, R. et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 34, 404\u2013410, https:\/\/doi.org\/10.1053\/jhep.2001.26511 (2001).","journal-title":"Hepatology"},{"key":"57603_CR8","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3748\/wjg.v24.i28.3181","volume":"24","author":"XW Jiang","year":"2018","unstructured":"Jiang, X. W., Ye, J. Z., Li, Y. T. & Li, L. J. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J. Gastroenterol. 24, 3181\u20133191, https:\/\/doi.org\/10.3748\/wjg.v24.i28.3181 (2018).","journal-title":"World J. Gastroenterol."},{"key":"57603_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM M\u00fccke","year":"2018","unstructured":"M\u00fccke, M. M. et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 3, 172\u2013180, https:\/\/doi.org\/10.1016\/S2468-1253(18)30002-5 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"57603_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/hepr.12919","volume":"47","author":"A Doi","year":"2017","unstructured":"Doi, A. et al. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol. Res. 47, 1438\u20131444, https:\/\/doi.org\/10.1111\/hepr.12919 (2017).","journal-title":"Hepatol. Res."},{"key":"57603_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2017.04.008","volume":"67","author":"N Kawagishi","year":"2017","unstructured":"Kawagishi, N. et al. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. J. Hepatol. 67, 1106\u20131108, https:\/\/doi.org\/10.1016\/j.jhep.2017.04.008 (2017).","journal-title":"J. Hepatol."},{"key":"57603_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/hepr.12905","volume":"47","author":"K Sato","year":"2017","unstructured":"Sato, K. et al. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatol. Res. 47, 1346\u20131353, https:\/\/doi.org\/10.1111\/hepr.12905 (2017).","journal-title":"Hepatol. Res."},{"key":"57603_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/cid\/civ474","volume":"61","author":"JM Collins","year":"2015","unstructured":"Collins, J. M. et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin. Infect. Dis. 61, 1304\u20131306, https:\/\/doi.org\/10.1093\/cid\/civ474 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"57603_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/hepr.12578","volume":"46","author":"H Takayama","year":"2016","unstructured":"Takayama, H., Sato, T., Ikeda, F. & Fujiki, S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection. Hepatol. Res. 46, 489\u2013491, https:\/\/doi.org\/10.1111\/hepr.12578 (2016).","journal-title":"Hepatol. Res."},{"key":"57603_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","volume":"61","author":"AM Di Bisceglie","year":"2015","unstructured":"Di Bisceglie, A. M. et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 61, 703\u2013711, https:\/\/doi.org\/10.1002\/hep.27609 (2015).","journal-title":"Hepatology"},{"key":"57603_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep27782","volume":"6","author":"T Nakabori","year":"2016","unstructured":"Nakabori, T. et al. Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci. Rep. 6, 27782, https:\/\/doi.org\/10.1038\/srep27782 (2016).","journal-title":"Sci. Rep."},{"key":"57603_CR17","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","volume":"34","author":"YM Loo","year":"2011","unstructured":"Loo, Y. M. & Gale, M. Immune signaling by RIG-I-like receptors. Immunity 34, 680\u2013692, https:\/\/doi.org\/10.1016\/j.immuni.2011.05.003 (2011).","journal-title":"Immunity"},{"key":"57603_CR18","doi-asserted-by":"publisher","first-page":"e1002289","DOI":"10.1371\/journal.ppat.1002289","volume":"7","author":"N Arnaud","year":"2011","unstructured":"Arnaud, N. et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7, e1002289, https:\/\/doi.org\/10.1371\/journal.ppat.1002289 (2011).","journal-title":"PLoS Pathog."},{"key":"57603_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1073\/pnas.0607038104","volume":"104","author":"DJ Lenschow","year":"2007","unstructured":"Lenschow, D. J. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371\u20131376, https:\/\/doi.org\/10.1073\/pnas.0607038104 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57603_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000353220","volume":"6","author":"R Pei","year":"2014","unstructured":"Pei, R. et al. Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J. Innate Immun. 6, 182\u2013191, https:\/\/doi.org\/10.1159\/000353220 (2014).","journal-title":"J. Innate Immun."},{"key":"57603_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","volume":"57","author":"HJ Dong","year":"2013","unstructured":"Dong, H. J. et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J. Clin. Virol. 57, 209\u2013214, https:\/\/doi.org\/10.1016\/j.jcv.2013.03.010 (2013).","journal-title":"J. Clin. Virol."},{"key":"57603_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","volume":"133","author":"S Kusumoto","year":"2019","unstructured":"Kusumoto, S. et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133, 137\u2013146, https:\/\/doi.org\/10.1182\/blood-2018-04-848044 (2019).","journal-title":"Blood"},{"key":"57603_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","volume":"11","author":"SW Choi","year":"2014","unstructured":"Choi, S. W. & Reddy, P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat. Rev. Clin. Oncol. 11, 536\u2013547, https:\/\/doi.org\/10.1038\/nrclinonc.2014.102 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"57603_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1158\/1940-6207.CAPR-15-0022-T","volume":"8","author":"H Hikita","year":"2015","unstructured":"Hikita, H. et al. Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prev. Res. (Phila.) 8, 693\u2013701, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-15-0022-T (2015).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"57603_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","volume":"84","author":"MA Sells","year":"1987","unstructured":"Sells, M. A., Chen, M. L. & Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl Acad. Sci. USA 84, 1005\u20131009 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57603_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-1-59745-394-3_23","volume":"510","author":"T Wakita","year":"2009","unstructured":"Wakita, T. Isolation of JFH-1 strain and development of an HCV infection system. Methods Mol. Biol. 510, 305\u2013327, https:\/\/doi.org\/10.1007\/978-1-59745-394-3_23 (2009).","journal-title":"Methods Mol. Biol."},{"key":"57603_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbrc.2011.01.042","volume":"405","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa, M. et al. The reconstituted \u2018humanized liver\u2019 in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 405, 405\u2013410, https:\/\/doi.org\/10.1016\/j.bbrc.2011.01.042 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"57603_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00535-018-01541-x","volume":"54","author":"A Doi","year":"2019","unstructured":"Doi, A. et al. Combinations of two drugs among NS3\/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. J. Gastroenterol. 54, 449\u2013458, https:\/\/doi.org\/10.1007\/s00535-018-01541-x (2019).","journal-title":"J. Gastroenterol."},{"key":"57603_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fmicb.2014.00208","volume":"5","author":"S Matsunaga","year":"2014","unstructured":"Matsunaga, S. et al. Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody. Front. Microbiol. 5, 208, https:\/\/doi.org\/10.3389\/fmicb.2014.00208 (2014).","journal-title":"Front. Microbiol."},{"key":"57603_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep17047","volume":"5","author":"K Okuyama-Dobashi","year":"2015","unstructured":"Okuyama-Dobashi, K. et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci. Rep. 5, 17047, https:\/\/doi.org\/10.1038\/srep17047 (2015).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57603-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:24:51Z","timestamp":1670307891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57603"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57603-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tetsuo Takehara received research grants and lecture fees from Bristol-Myers Squibb. Hayato Hikita received research grants from Bristol-Myers Squibb. Other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"941"}}